Ausgabe 2/2015
Inhalt (23 Artikel)
Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target?
Álvaro Henrique Ingles Garces, Mariane Sousa Fontes Dias, Eduardo Paulino, Carlos Gil Moreira Ferreira, Andréia Cristina de Melo
Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells
Lāsma Ivanova, Elīna Zandberga, Karīna Siliņa, Zane Kalniņa, Artūrs Ābols, Edgars Endzeliņš, Ineta Vendina, Nadezhda Romanchikova, Alinta Hegmane, Pēteris Trapencieris, Jānis Eglītis, Aija Linē
Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum
Ji Hyun Park, Jae-Lyun Lee
Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer
Ying Wang, Ping Liu, Yan Xu, Weihao Zhang, Lina Tong, Zhi Guo, Hong Ni
Antitumor efficacy of tangeretin by targeting the oxidative stress mediated on 7,12-dimethylbenz(a) anthracene-induced proliferative breast cancer in Sprague–Dawley rats
Kuppusamy Periyasamy, Kuppusamy Baskaran, Aruldass Ilakkia, Kalappan Vanitha, Sundaramoorthy Selvaraj, Dhanapal Sakthisekaran
Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage
Katsuya Makihara, Sayaka Azuma, Nobuyuki Kawato, Hiroyuki Ueno, Izumi Nakata
Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters
Jannick Clemens, Anja Seckinger, Dirk Hose, Dirk Theile, Magdalena Longo, Walter Emil Haefeli, Jürgen Burhenne, Johanna Weiss
A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002)
Masashi Kanai, Etsuro Hatano, Shogo Kobayashi, Yutaka Fujiwara, Shigeru Marubashi, Atsushi Miyamoto, Hisanori Shiomi, Shoji Kubo, Shinichi Ikuta, Hiroaki Yanagimoto, Hiroaki Terajima, Hisashi Ikoma, Daisuke Sakai, Yuzo Kodama, Satoru Seo, Satoshi Morita, Tetsuo Ajiki, Hiroaki Nagano, Tatsuya Ioka
Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer
Xi Gu, Yang Zhang, Long Chen, Jiao Guo, Wen-Hai Zhang
A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA)
Yoon-Koo Kang, Baek-Yeol Ryoo, Shinkyo Yoon, Lin Shen, Jooyun Lee, Chenlu Wei, Yu Zhou, Min-Hee Ryu
Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02
F. Rivera, B. Massutí, M. Salcedo, J. Sastre, J. Martínez Galán, M. Valladares-Ayerbes, R. Serrano, Mª. L. García de Paredes, J. L. Manzano, M. Galán, M. Alsina, A. L. Yuste Izquierdo, C. López, E. Díaz-Rubio, V. Conde, M. Reboredo, Mª. T. Cano, V. Pachón, E. Aranda
Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity
Nimit Singhal, Sina Vatandoust, Michael P. Brown
Pharmacokinetic/pharmacodynamic-based decision making in the development of MK-0888, a VEGFR-2/FLT-3 kinase inhibitor
Marian Iwamoto, Evan J. Friedman, Laura Sepp-Lorenzino, Jennifer E. Talaty, Nancy G. B. Agrawal, John A. Wagner
A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors
Hope E. Uronis, Jingquan Jia, Johanna C. Bendell, Leigh Howard, Neal A. Ready, Paula H. Lee, Mark D. Starr, Andrew Dellinger, Herbert Pang, Andrew B. Nixon, Herbert I. Hurwitz
Oxymatrine targets EGFRp-Tyr845 and inhibits EGFR-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells
Bingyu Guo, Tingting Zhang, Jingyuan Su, Kaiwen Wang, Xiaoming Li
Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules
P. Hamberg, R. H. J. Mathijssen, P. de Bruijn, C. Leonowens, D. van der Biessen, F. A. L. M. Eskens, S. Sleijfer, J. Verweij, M. J. A. de Jonge
A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer
Kazuhiro Suzuki, Seiichiro Ozono, Akito Yamaguchi, Hidekazu Koike, Hiroshi Matsui, Masao Nagata, Takatoshi Takubo, Kana Miyashita, Takafumi Matsushima, Hideyuki Akaza
Novel FTS-diamine/cinnamic acid hybrids inhibit tumor cell proliferation and migration and promote apoptosis via blocking Ras-related signaling in vitro
Yong Ling, Xinmei Zhao, Xianghua Li, Xuemin Wang, Yang Yang, Zhiqiang Wang, Xinyang Wang, Jie Zhang, Yihua Zhang
Prevalence and clinical significance of potential drug–drug interaction in hematopoietic stem cell transplantation
Danilo D. Trevisan, Juliana B. Silva, Henrique C. Oliveira, Silvia R. Secoli, Maria Helena M. Lima
Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer
Marie T. Borin, Meng Chen, Simonetta Mocci, Igor Rubets, Jason Chittenden, Wassim Aldairy, Mark Stroh
Cks1 proteasomal degradation is induced by inhibiting Hsp90-mediated chaperoning in cancer cells
Vinayak Khattar, Joshua Fried, Bo Xu, Jaideep V. Thottassery
CEACAM1 and hollow spheroid formation modulate the chemosensitivity of colorectal cancer to 5-fluorouracil
Naoyuki Yamamoto, Shozo Yokoyama, Junji Ieda, Yasuyuki Mitani, Shunsuke Yamaguchi, Katsunari Takifuji, Tsukasa Hotta, Kenji Matsuda, Takashi Watanabe, John E. Shively, Hiroki Yamaue
Novel in silico-designed estradiol analogues are cytotoxic to a multidrug-resistant cell line at nanomolar concentrations
Anne Theron, Renaud Prudent, Elsie Nolte, Iman van den Bout, Rivak Punchoo, Sumari Marais, Peet du Toit, Yvette Hlophe, Dirk van Papendorp, Laurence Lafanechère, Annie Joubert